Search the Newsreel

CEO da United Therapeutics vende US$ 5,05 milhões em ações - Investing.com Brasil

Projeções de Resultados: United Therapeutics Corp (UTHR) — LPA e Crescimento de Receita

Notícias das Ações da United Therapeutics Corp (UTHR)

Is United Therapeutics Corp (UTHR) Overvalued After Q2 Earnings

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points United Therapeutics Corp (NASDAQ:UTHR) reported exceptional clinical results from its advanced outcomes study, demonstrating ralinepag's …

How Investors May Respond To United Therapeutics (UTHR) EPS Strength And Ralinepag’s Phase 3 Milestone

In the past week, United Therapeutics reported second-quarter 2026 results showing sales of US$783.3 million, a slight year-on-year decline, while net income rose to US$333 million and diluted EPS increased to US$7.27, alongside continued share repurchases under its US$1.50 billion buyback program. At the …

United Therapeutics' Q2 Tyvaso Miss Reflects Competition; IPF Outreach Set to Expand, Morgan Stanley Says

United Therapeutics' (UTHR) Q2 miss for Tyvaso reflected pressure from rising competition, though th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark

United Therapeutics UTHR reported second-quarter 2026 earnings per share (EPS) of $7.27, beating the Zacks Consensus Estimate of $6.82. Bottom line increased 13.4% year over year. United Therapeutics markets four products for pulmonary arterial hypertension (PAH): Tyvaso, Orenitram, Adcirca and Remodulin. It also markets …

United Therapeutics: EPS sobe 13% no 2º trimestre fiscal de 2026

United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales

United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street's expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 million. Its GAAP profit of $7.27 per share was 5.9% above …

United Therapeutics Corporation Reports Second Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 05, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent …

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary endpoints with statistical significance The results support the use of ralinepag as a once-daily oral prostacyclin receptor agonist …

United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corporation (NASDAQ:UTHR), sold 9,500 shares of common stock on July 27, 2026, for proceeds totaling $5.0 million. SEC Form 4 filing. Transaction summary Metric Value Shares sold (indirectly held) 9,500 Transaction value $5.0 million Post-transaction …

Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

Liquidia Corporation LQDA is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics UTHR boasts six FDA-approved therapies that treat PAH, PH-ILD, and neuroblastoma, a rare pediatric …

United Therapeutics Appoints Victor Dzau To Board Of Directors

(RTTNews) - United Therapeutics Corporation (UTHR), announced on Thursday the appointment of Victor Dzau to its Board, effective immediately. Dzau recently completed a 12-year term as President at the National Academy of Medicine and currently serves as Professor of Medicine and Director of the …

Liquidia jumps as judge criticizes United Therapeutics in patent dispute

[Judge Gavel Beside Open Law Book With Turning Pages] jittawit.21/iStock via Getty Images Liquidia Corp. (LQDA [https://seekingalpha.com/symbol/LQDA]) rose 8% after a judge in a long-standing patent dispute with United Therapeutics (UTHR [https://seekingalpha.com/symbol/UTHR]) criticized the company's lawyers in a legal filing. United Therapeutics ticked lower …

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

The market expects United Therapeutics (UTHR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might …

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 22, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 …

As ações da United Therapeutics caem após receita abaixo do esperado, apesar dos resultados superarem as expectativas

Stock United Therapeutics - Stock UTHR - Resultados, Dividendos, Cotação e Indicadores